Glaukos Completes Patient Enrollment In US 510(k) Pivotal Study Evaluating PRESERFLO MicroShunt In Adult Patients With Primary Open-Angle Glaucoma Who Failed Previous Medical And Surgical Treatment
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the
Glaukos finished signing up all the patients they needed to test a new glaucoma device called PRESERFLO MicroShunt. This is an important checkpoint—it means they can now move forward with proving whether it works, which is a key step before doctors can use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.